Key facts
- This page summarizes Anna Protopapas's Form 4 filing for Dicerna Pharmaceuticals Inc.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jun 2021, 21:34.
Anna Protopapas - 03 Jun 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 03 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2021, 21:34:18 UTC
- Next SEC filing
- 19 Jul 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Douglas W. Pagan, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Anna Protopapas filed Form 4 for Dicerna Pharmaceuticals Inc on 07 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,333
- Change %
- Price
- Shares after
- 3,333
- Date
- 03 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DRNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,333
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,333
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Anna Protopapas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.